Tags: Salix Pharmaceuticals Ltd
Salix Pharma to restate past seven quarters' results
Salix Pharmaceuticals Ltd said it would restate financial statements for all of 2013 and the first three quarters of 2014, adding to the drugmaker's list of woes.
Salix Pharma working with advisers to explore options - sources
Salix Pharmaceuticals Ltd SXLP.O, a maker of bowel drugs, is working with investment bank Centerview Partners Holdings LP to explore its options, including a potential sale to a larger drugmaker, according to three people familiar with the matter.
Allergan near buyout of up to $65 billion to escape Valeant, Ackman: source
Allergan Inc is close to a buyout deal worth up to $65.5 billion by Actavis Plc, one that could end months of pursuit by Canada’s Valeant Pharmaceuticals and William Ackman's hedge fund, Pershing Square Capital Management, according to a person familiar with the matter.
Actavis plans new merger approach for Allergan - sources
Actavis Plc (ACT.N) plans to approach Allergan Inc (AGN.N) again about a potential merger, as the Botox maker warms up to the possibility of a sale, people familiar with the matter said on Tuesday.
